| pubmed-article:15627886 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15627886 | lifeskim:mentions | umls-concept:C0152013 | lld:lifeskim |
| pubmed-article:15627886 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:15627886 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:15627886 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:15627886 | pubmed:issue | 5-6 | lld:pubmed |
| pubmed-article:15627886 | pubmed:dateCreated | 2005-1-3 | lld:pubmed |
| pubmed-article:15627886 | pubmed:abstractText | The tyrosine-kinase receptor c-kit (CD117) and its ligand stem cell factor are considered to be co-expressed in various solid tumors, including adenocarcinomas of the lung. The frequency of c-kit expression and its association with clinical parameters has not yet been evaluated in a larger population of lung adenocarcinomas. Therefore, tumor tissue of 95 consecutive patients with adenocarcinoma of the lung was stained using a polyclonal c-kit antibody. c-kit expression was correlated with relevant clinical parameters obtained by chart review. Positive c-kit expression in tumor tissue was observed in 61 of 95 patients (64%). Univariate analysis showed a significant effect of T (p = 0.003), N (p = 0.001) and M stage (p < 0.001) as well as of performance status (p = 0.001), surgical resection (p < 0.001), and LDH serum levels (p = 0.016) on survival. In contrast, c-kit protein expression was non- significant (p = 0.913). However, multivariate Cox regression with the influential parameters revealed a significant effect of c-kit expression on survival. Forward stepwise selection showed a 1.77-fold increased risk to die (hazard ratio, HR; 95% confidence interval, CI: 1.00-3.14, p = 0.047) for patients with c-kit-positive tumors. Similar data for c-kit expression were obtained by backward stepwise selection (HR: 1.78; 95% CI: 1.00-3.16; p = 0.044). In conclusion, the receptor tyrosine kinase c-kit is frequently expressed in adenocarcinomas of the lung and has a relevant effect on patient survival. The results of this study support clinical trials targeting the c-kit receptor with specific c-kit inhibitors (e.g. imatinib). | lld:pubmed |
| pubmed-article:15627886 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15627886 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15627886 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15627886 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15627886 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15627886 | pubmed:issn | 1010-4283 | lld:pubmed |
| pubmed-article:15627886 | pubmed:author | pubmed-author:BittingerFern... | lld:pubmed |
| pubmed-article:15627886 | pubmed:author | pubmed-author:WiewrodtRaine... | lld:pubmed |
| pubmed-article:15627886 | pubmed:author | pubmed-author:FischerBertho... | lld:pubmed |
| pubmed-article:15627886 | pubmed:author | pubmed-author:FaldumAndreas... | lld:pubmed |
| pubmed-article:15627886 | pubmed:author | pubmed-author:BuhlRolandR | lld:pubmed |
| pubmed-article:15627886 | pubmed:author | pubmed-author:MickePatrickP | lld:pubmed |
| pubmed-article:15627886 | pubmed:author | pubmed-author:HengstlerJan... | lld:pubmed |
| pubmed-article:15627886 | pubmed:author | pubmed-author:BeckerKaiK | lld:pubmed |
| pubmed-article:15627886 | pubmed:author | pubmed-author:AlbrechtHeidi... | lld:pubmed |
| pubmed-article:15627886 | pubmed:copyrightInfo | Copyright 2004 S. Karger AG, Basel. | lld:pubmed |
| pubmed-article:15627886 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15627886 | pubmed:volume | 25 | lld:pubmed |
| pubmed-article:15627886 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15627886 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15627886 | pubmed:pagination | 235-42 | lld:pubmed |
| pubmed-article:15627886 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:meshHeading | pubmed-meshheading:15627886... | lld:pubmed |
| pubmed-article:15627886 | pubmed:articleTitle | c-kit expression in adenocarcinomas of the lung. | lld:pubmed |
| pubmed-article:15627886 | pubmed:affiliation | Institute of Legal Medicine and Rudolf Boehm Institute of Pharmacology and Toxicology, Leipzig, Germany. patrick.micke@licr.uu.se | lld:pubmed |
| pubmed-article:15627886 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15627886 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15627886 | lld:pubmed |
